¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"central nervous system agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • static system
    Á¤Áö°è
  • scavenging system
    Á¦°Åü°è, û¼Òü°è
  • stereotactic system
    1. Á¤À§°íÁ¤±â 2. Á¤À§Ã¼°è, ÀÔüü°è
  • superficial musculo-aponeurotic system
    ¾ó±¼³ÎÈûÁÙ°èÅë, Ç¥Àç±Ù°Ç¸·°èÅë
  • superficial musculo-aponeurotic system platysma flap
    ¾ó±¼³ÎÈûÁÙ°èÅë³ÐÀº¸ñ±ÙÆÇ, Ç¥Àç±Ù°Ç¸·°èÅëȰ°æ±ÙÆÇ
  • system
    1. °èÅë, °è, ü°è 2. ÀåÄ¡ 3. Á¦µµ, ¹ý 4. ºÐ·ù¹ý
  • system analysis
    °èÅëºÐ¼®
  • self-system
    ÀÚ±âü°è
  • skeletal system
    »À´ë°èÅë, °ñ°Ý°è
  • social security system
    »çȸº¸ÀåÁ¦µµ
  • urinary system
    ºñ´¢°èÅë, ºñ´¢°è
  • urogenital system
    ºñ´¢»ý½Ä±â°èÅë, ºñ´¢»ý½Ä±â°è
  • vascular system
    Ç÷°ü°èÅë, Ç÷°ü°è
  • value system
    °¡Ä¡Ã¼°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • limbic system
    °¡ÀåÀÚ¸®°èÅë, º¯¿¬°è
  • local health system
    Áö¹æÀÇ·áü°è
  • lymphatic system
    ¸²ÇÁ°èÅë
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë
  • major histocompatibility system
    ÁÖÁ¶Á÷ÀûÇÕ°è
  • metric system
    ¹ÌÅ͹ý
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë
  • musculoskeletal system
    ±ÙÀ°°ñ°Ý°èÅë
  • nonrecirculating system
    ºñÀç¼øÈ¯½Äȸ·Î
  • nonspecific sensory system
    ºñƯÁ¤°¨°¢°è
  • oil immersion system
    À¯Ä§ÀåÄ¡
  • open system
    °³¹æÁ¦, °³¹æ½Ã½ºÅÛ, °³¹æÇüº´¿ø
  • optical system
    ±¤Çаè
  • oscillating system
    Áøµ¿°è
  • oxidation-reduction system
    »êȭȯ¿ø°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • renin-angiotensin system
    ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè(¡­Ìõ)
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ðü°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • central medial nucleus
    ¾ÈÂÊÁß½ÉÇÙ
  • central microtubule
    Á߽ɹ̼¼°ü
  • central necrosis
    Á᫐ ±«»ç
  • central neurogenic hyperpnea
    ÁßÃ߽Ű漺°úÈ£Èí.
  • central nucleus
    Áß½ÉÇÙ
  • central obesity
    Á߽ɺκñ¸¸(Áõ), ±¸°£ºñ¸¸.
  • central pain
    ÁßÃß¼º µ¿Åë.
  • central pain
    ÁßÃß¼ºÅëÁõ
  • central papillary atrophy
    Á᫐ À¯µÎ À§Ãà
  • central part
    Á߽ɺκÐ
  • central pit
    Á߽ɿÀ¸ñ, Á߽ɼҿÍ(¡­á³èÀ).
  • central point artifact
    Áß½ÉÁ¡ Àΰø¹°
  • central pontine myelinolysis
    ³ú±³ Á߽ɺΠ¼öÃÊ¿ëÇØÁõ
  • central pontine myelinolysis
    ³ú±³¼öÃÊ¿ëÇØ(Òà±³¼öÃÊéÁú°)
  • central pulse
    Áß½É¸Æ¹Ú (¡­ØæÚÑ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
SCS Saethre-Chotzen syndrome; shared computer system; silicon-controlled switch; Society of Clinical Sur...
SIS semantic indexing system; serotinin irritation syndrome; simian sarcoma; simulator-induced syndrome;...
SMAS submuscular aponeurotic system; superficial musculo-aponeurotic system; superior mesenteric artery s...
CP Central Pool
CRAO Central Retina Artery Occlusion
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
CSA Central sleep apnea
CVP Central venous
CVAD Central venous access devices
CVC Central venous catheterisation
CVL central venous line
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • fingerprint system
    Áö¹®°è
  • fusimotor system
    ¹æÃß ¿îµ¿°è
  • human system
    ÀÎü°è
  • hypophyseal portal system
    ³úÇϼöü ¹®¸Æ °èÅë, Çϼöü ¹®¸Æ°è
  • hypothalamohypophyseal system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • hypothalamopituitary system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • hypothalamus pituaitary system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • immune system
    ¸é¿ª °èÅë, ¸é¿ª°è
    °¨¿°À̳ª Áúº´À¸·ÎºÎÅÍ ½Åü¸¦ ¹æ¾îÇϴµ¥ °ü¿©ÇÏ´Â ¿©·¯ ¼¼Æ÷¿Í Àå±â Áý´Ü.
  • immunologic system
    ¸é¿ª°è
    ¼¼Æ÷ ¼ººÐ ¹× ºÐÀÚ ¼ººÐÀÇ º¹ÇÕ Ã¼°è·Î¼­ ÀÌÀÇ ÀÏÂ÷ ±â´ÉÀº Àڱ⸦ ºñÀÚ±â·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ »ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇÏ´Â °ÍÀÌ´Ù.
  • implant system
    ÀÓÇöõÆ® ½Ã½ºÅÛ
  • improved classificaion system
    °³¼±µÈ ºÐ·ù ü°è
  • kinesodic system
    ô¼ö ¿îµ¿°è
  • kinetic system
    ¿îµ¿°è
    ³ú, °©»ó¼±, ºÎ½Å, °£, ÃéÀå µîÀÇ ±â°ü°èÅëÀ¸·Î, ÀáÀç·ÂÀ» ¿îµ¿°ú ¿­·Î º¯È­½ÃŰ´Â ±â´ÉÀ» ³ªÅ¸³½´Ù. ´Éµ¿Àû ¿îµ¿À» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ½Å°æ±Ù°è.
  • lacrimal system
    ´«¹° ±â°ü
  • length monitoring system
    ±æÀÌ °¨Áö°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
neurotransmitter agents Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
(12 Dec 1998)
neurotransmitters and neurotransmitter agents A collective grouping for neurotransmitters and substances that act on the neurotransmitter system.
(12 Dec 1998)
nootropic agents Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.
(12 Dec 1998)
sunscreening agents Chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation.
(12 Dec 1998)
sweetening agents Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products.
(12 Dec 1998)
dentin-bonding agents Cements that act through infiltration and polymerization within the dentinal matrix and are used for dental restoration. They can be adhesive resins themselves, adhesion-promoting monomers, or polymerization initiators that act in concert with other agents to form a dentin-bonding system.
(12 Dec 1998)
dermatologic agents Drugs used to treat or prevent skin disorders or for the routine care of skin.
(12 Dec 1998)
dopamine agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
(12 Dec 1998)
imaging agents Proteins developed to act as imaging or contrast agents for use with various types of bodyscanners. The proteins, usually antibodies, bind to specific tissue types, usually tumours, and allow the scanner to distinguish those tissues from the surrounding tissue very easily.
(14 Nov 1997)
immunosuppressive agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging.
(12 Dec 1998)
intercalating agents Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA.
(12 Dec 1998)
iron chelating agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of haemoglobin is an example of a metal chelate found in biological systems.
(12 Dec 1998)
tocolytic agents Drugs that prevent preterm labour and immature birth by suppressing uterine contractions. Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete.
(12 Dec 1998)
embedding agents Materials such as celloidin, paraffin, etc. In which specimens of tissue are set before being cut into sections for microscopic examination.
(05 Mar 2000)
TRIC agents Strains of Chlamydia trachomatis that cause trachoma and inclusion conjunctivitis agents
See: Chlamydia trachomatis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á